Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tenax Therapeutics (TENX) Liabilities and Shareholders Equity (2016 - 2017)

Tenax Therapeutics' Liabilities and Shareholders Equity history spans 6 years, with the latest figure at $11.0 million for Q3 2017.

  • For Q3 2017, Liabilities and Shareholders Equity fell 81.57% year-over-year to $11.0 million; the TTM value through Dec 2017 reached $43.6 million, down 70.37%, while the annual FY2016 figure was $23.3 million, N/A changed from the prior year.
  • Liabilities and Shareholders Equity for Q3 2017 was $11.0 million at Tenax Therapeutics, down from $13.4 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $73.0 million in Q4 2015 and bottomed at $3.0 million in Q1 2013.
  • The 4-year median for Liabilities and Shareholders Equity is $21.2 million (2016), against an average of $33.4 million.
  • The largest annual shift saw Liabilities and Shareholders Equity plummeted 48.34% in 2013 before it crashed 81.57% in 2017.
  • A 4-year view of Liabilities and Shareholders Equity shows it stood at $3.0 million in 2013, then soared by 2298.65% to $73.0 million in 2015, then tumbled by 68.02% to $23.3 million in 2016, then crashed by 52.86% to $11.0 million in 2017.
  • Per Business Quant, the three most recent readings for TENX's Liabilities and Shareholders Equity are $11.0 million (Q3 2017), $13.4 million (Q2 2017), and $19.2 million (Q1 2017).